EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis

Effekte von Sodium-Glucose-Cotransporter-2-Inhibitoren bei Patient:innen mit Krebs und Diabetes mellitus: systematische Übersicht und Metaanalyse

Giuseppina Novo, Cristina Madaudo iD, Antonio Cannatà, Pietro Ameri iD, Daniela Di Lisi, Daniel I Bromage, Alfredo Ruggero Galassi, Giorgio Minotti iD, Alexander R Lyon

European Heart Journal - Cardiovascular Pharmacotherapy · 07.07.2025 · 11 (4) · 343-352

DOI: 10.1093/ehjcvp/pvaf028 ↗

Auf einen Blick

Bei aktiv behandelten Krebspatient:innen mit Typ-2-Diabetes war die Anwendung von SGLT2i mit geringerer Gesamtmortalität und weniger HF-Hospitalisierungen verbunden.

Fragestellung

Welche kardiovaskulären Effekte haben SGLT2i bei Krebspatient:innen mit Typ-2-Diabetes unter Chemotherapie im Vergleich ohne SGLT2i?

Methode

Systematische Übersicht und Metaanalyse von 11 retrospektiven Beobachtungsstudien; Bewertung mit dem National Institutes of Health Quality Assessment Tool.

Ergebnisse

11 retrospektive Studien mit n = 104 327 Patient:innen. Gesamtmortalität: 0,47 (95 %-KI 0,33–0,67; P < 0,0001). HF-Hospitalisierung: 0,44 (95 %-KI 0,27–0,72; P = 0,001).

Schlussfolgerung der Autor:innen

Die Autor:innen folgern, dass SGLT2i mit einer signifikanten Reduktion von Gesamtmortalität und HF-Hospitalisierung bei aktiv behandelten Krebspatient:innen mit Typ-2-Diabetes verbunden sein könnten.

Kernaussagen

  • 11 retrospektive Studien wurden ausgewertet
  • Geringere Gesamtmortalität unter SGLT2i: 0,47 (95 %-KI 0,33–0,67)
  • Weniger HF-Hospitalisierungen unter SGLT2i: 0,44 (95 %-KI 0,27–0,72)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 25.04.2025. Verfasst von Giuseppina Novo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, University Hospital 'Paolo Giaccone', Via del vespro 129, 90127 Palermo, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Diabetes Mellitus, Type 2, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Leducq Network of Excellence in Cardio-Oncology, Royal Brompton Cardio-Oncology Centre of Excellence, The Big Heart Foundation.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cardiovascular disease and cancer represent significant global health challenges. An overlap between oncology and cardiology is compounded by cancer therapies, which are known to have cardiotoxic effects. Sodium–glucose cotransporter 2 inhibitors (SGLT2i), initially developed for treating diabetes, have shown promising cardiovascular benefits in non-cancer populations, particularly in preventing heart failure (HF) and reducing HF-related hospitalization and mortality in large randomized controlled trials (RCTs) across the spectrum of left ventricular ejection fraction. However, their potential cardioprotective role in cancer patients remains unclear. This systematic review and meta-analysis evaluated cardiovascular outcomes in cancer patients with type 2 diabetes undergoing chemotherapy with concomitant use of SGLT2i compared with those not using SGLT2i. Subgroup analyses were performed to explore patients without baseline HF and patients treated exclusively with anthracyclines. Methods and results A systematic review identified 11 observational retrospective studies (n = 104 327 patients). Based on the National Institutes of Health Quality Assessment Tool checklist, two studies were at moderate risk of bias, while all other included studies had a low risk of bias. Meta-analysis indicated that the use of SGLT2i was associated with a significant reduction in all-cause mortality [0.47, 95% confidence interval (CI) 0.33–0.67, P < 0.0001] and risk of HF hospitalization (0.44, 95% CI 0.27–0.72, P = 0.001).

Conclusion

The use of SGLT2i may be associated with a significant reduction in all-cause mortality and risk of HF hospitalization in actively treated cancer patients with Type 2 diabetes. Our study highlights the need for further investigation through prospective RCTs to confirm the efficacy and safety of SGLT2i in attenuating cardiotoxicity and supporting cardiovascular health in oncology settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsNeoplasmsDiabetes Mellitus, Type 2Antineoplastic AgentsHumansTreatment OutcomeCardiotoxicityRisk FactorsRisk AssessmentFemaleMaleMiddle AgedAgedObservational Studies as Topic

Stichwörter der Autor:innen

Cancer therapy-related cardiac dysfunction (CTRCD)Cardio-oncologyCardiotoxicityHeart failure hospitalizationPreventive cardiologySGLT2 inhibitors (SGLT2i)

Substanzen

Sodium-Glucose Transporter 2 InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Cardiology Unit, University Hospital 'Paolo Giaccone', Via del vespro 129, 90127 Palermo, Italy.
  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy.
  • Department of Cardiovascular Sciences, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, The James Black Centre, 125 Coldharbour L…
  • Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, 16132 Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132 Genoa, Italy.
  • Department of Medicine and Unit of Clinical Pharmacology, University and Fondazione Policlinico Universitario Campus Bio-Medico, Via Álvaro del Portillo 200, 00128 Rome, Italy.

ORCID-Profile: Cristina Madaudo, Pietro Ameri, Giorgio Minotti

Förderung

  • Fondation Leducq Network of Excellence in Cardio-Oncology
  • Royal Brompton Cardio-Oncology Centre of Excellence
  • The Big Heart Foundation

Zitieren

APA

Novo, G., Madaudo, C., Cannatà, A., Ameri, P., Di Lisi, D., Bromage, D. I., Galassi, A. R., Minotti, G., & Lyon, A. R. (2025). Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 11(4), 343-352. https://doi.org/10.1093/ehjcvp/pvaf028

Vancouver

Novo G, Madaudo C, Cannatà A, Ameri P, Di Lisi D, Bromage DI, et al. Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2025;11(4):343-352. doi:10.1093/ehjcvp/pvaf028

BibTeX
@article{Novo2025,
  author = {Novo, Giuseppina and Madaudo, Cristina and Cannatà, Antonio and Ameri, Pietro and Di Lisi, Daniela and Bromage, Daniel I and Galassi, Alfredo Ruggero and Minotti, Giorgio and Lyon, Alexander R},
  title = {Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  volume = {11},
  number = {4},
  pages = {343--352},
  doi = {10.1093/ehjcvp/pvaf028}
}
Kostenlos starten →